Avalo Therapeutics (AVTX) Equity Income (2019 - 2020)
Avalo Therapeutics posted quarterly Equity Income of -$1.9 million for Q2 2020, down 126.44% on a QoQ basis from $7.1 million in Q1 2020.
Avalo Therapeutics (AVTX) has 2 years of Equity Income data on file, last reported at -$1.9 million in Q2 2020.
- For the quarter ending Q2 2020, Equity Income changed N/A year-over-year to -$1.9 million; the trailing twelve-month figure through Mar 2021 stood at -$1.9 million (down 126.24% YoY), and the FY2020 full-year result was $5.2 million, up 9556.6% from the prior year.
- Equity Income for Q2 2020 stood at -$1.9 million, down from $7.1 million in the prior quarter.
- Across five years, Equity Income topped out at $7.1 million in Q1 2020 and bottomed at -$1.9 million in Q2 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 235,807.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Avalo Therapeutics | 317.29 Mn | 317.29 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2020 | -1.87 Mn |
| Mar 31, 2020 | 7.08 Mn |
| Dec 31, 2019 | 53,932.00 |